sulfaphenazole has been researched along with Disease Models, Animal in 9 studies
Sulfaphenazole: A sulfonilamide anti-infective agent.
sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to discover and develop drug-like anti-inflammatory agents against arthritis, based on "Hit" we found earlier and to overcome drawbacks of toxicity, twelve series of total 89 novel pyrimidine, pyrazolo[4,3-d]pyrimidine and thieno[3,2-d]pyrimidine derivatives were designed, synthesized and screened for their anti-inflammatory activity against NO and toxicity for normal liver cells (LO2)." | 8.02 | Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. ( Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL, 2021) |
| "The objective of this study was to establish the cardioprotective effect of sulfaphenazole (SPZ), a selective inhibitor of cytochrome P450 2C9 enzyme, in an in vivo rat model of acute myocardial infarction (MI)." | 7.75 | Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation. ( Hamlin, RL; Khan, M; Kotha, SR; Kuppusamy, P; Kutala, VK; Mohan, IK; Parinandi, NL, 2009) |
| "Sulfaphenazole (SPZ) has a different mechanism such as reactive oxygen species scavenging, in addition to the inhibition of superoxide production by cytochrome P450." | 5.38 | Effects of sulfaphenazole after collagenase-induced experimental intracerebral hemorrhage in rats. ( Danjo, S; Hama, S; Ishihara, Y; Itoh, K; Nakamura, Y; Watanabe, M, 2012) |
| "In order to discover and develop drug-like anti-inflammatory agents against arthritis, based on "Hit" we found earlier and to overcome drawbacks of toxicity, twelve series of total 89 novel pyrimidine, pyrazolo[4,3-d]pyrimidine and thieno[3,2-d]pyrimidine derivatives were designed, synthesized and screened for their anti-inflammatory activity against NO and toxicity for normal liver cells (LO2)." | 4.02 | Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. ( Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL, 2021) |
| "The objective of this study was to establish the cardioprotective effect of sulfaphenazole (SPZ), a selective inhibitor of cytochrome P450 2C9 enzyme, in an in vivo rat model of acute myocardial infarction (MI)." | 3.75 | Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation. ( Hamlin, RL; Khan, M; Kotha, SR; Kuppusamy, P; Kutala, VK; Mohan, IK; Parinandi, NL, 2009) |
| "Sulfaphenazole (SPZ) has a different mechanism such as reactive oxygen species scavenging, in addition to the inhibition of superoxide production by cytochrome P450." | 1.38 | Effects of sulfaphenazole after collagenase-induced experimental intracerebral hemorrhage in rats. ( Danjo, S; Hama, S; Ishihara, Y; Itoh, K; Nakamura, Y; Watanabe, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| O' Neill, PM | 1 |
| Stocks, PA | 1 |
| Sabbani, S | 1 |
| Roberts, NL | 1 |
| Amewu, RK | 1 |
| Shore, ER | 1 |
| Aljayyoussi, G | 1 |
| Angulo-Barturén, I | 1 |
| Belén, M | 1 |
| Bazaga, SF | 1 |
| Martínez, MS | 1 |
| Campo, B | 1 |
| Sharma, R | 1 |
| Charman, SA | 1 |
| Ryan, E | 1 |
| Chen, G | 1 |
| Shackleford, DM | 1 |
| Davies, J | 1 |
| Nixon, GL | 1 |
| Biagini, GA | 1 |
| Ward, SA | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Xue, ST | 1 |
| Zhang, L | 1 |
| Xie, ZS | 1 |
| Jin, J | 1 |
| Guo, HF | 1 |
| Yi, H | 1 |
| Liu, ZY | 1 |
| Li, ZR | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Chen, LZ | 1 |
| Shu, HY | 1 |
| Wu, J | 1 |
| Yu, YL | 1 |
| Ma, D | 1 |
| Huang, X | 1 |
| Liu, MM | 1 |
| Liu, XH | 1 |
| Shi, JB | 1 |
| Wang, S | 1 |
| Zhang, S | 1 |
| Xu, C | 1 |
| Barron, A | 1 |
| Galiano, F | 1 |
| Patel, D | 1 |
| Lee, YJ | 1 |
| Caldwell, GA | 1 |
| Caldwell, KA | 1 |
| Witt, SN | 1 |
| Khan, M | 1 |
| Mohan, IK | 1 |
| Kutala, VK | 1 |
| Kotha, SR | 1 |
| Parinandi, NL | 1 |
| Hamlin, RL | 1 |
| Kuppusamy, P | 1 |
| Huang, C | 1 |
| Liu, W | 1 |
| Perry, CN | 1 |
| Yitzhaki, S | 1 |
| Lee, Y | 1 |
| Yuan, H | 1 |
| Tsukada, YT | 1 |
| Hamacher-Brady, A | 1 |
| Mentzer, RM | 1 |
| Gottlieb, RA | 1 |
| Hama, S | 1 |
| Ishihara, Y | 1 |
| Watanabe, M | 1 |
| Danjo, S | 1 |
| Nakamura, Y | 1 |
| Itoh, K | 1 |
9 other studies available for sulfaphenazole and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
Topics: Administration, Oral; Animals; Antimalarials; Disease Models, Animal; Drug Stability; Humans; Inhibi | 2018 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
Topics: Animals; Benzofurans; Bone Morphogenetic Protein 2; Caco-2 Cells; Disease Models, Animal; Dose-Respo | 2020 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
Topics: Administration, Oral; Animals; Arthritis; Cells, Cultured; Dimerization; Disease Models, Animal; Dos | 2021 |
Chemical Compensation of Mitochondrial Phospholipid Depletion in Yeast and Animal Models of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Carboxy-Lyases; C | 2016 |
Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation.
Topics: Animals; Biological Availability; Blood Pressure; Blotting, Western; Cardiotonic Agents; Disease Mod | 2009 |
Autophagy and protein kinase C are required for cardioprotection by sulfaphenazole.
Topics: Adenoviridae; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Autophagy; Autophagy-Related Pr | 2010 |
Effects of sulfaphenazole after collagenase-induced experimental intracerebral hemorrhage in rats.
Topics: Animals; Behavior, Animal; Brain Edema; Cerebral Hemorrhage; Collagenases; Disease Models, Animal; L | 2012 |